Get the Stockscreener App
145.24
2.40%
-3.57
After Hours:
145.24
Repligen Corp stock is traded at $145.24, with a volume of 930.95K.
It is down -2.40% in the last 24 hours and up +20.80% over the past month.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
See More
Previous Close:
$148.81
Open:
$148.33
24h Volume:
930.95K
Relative Volume:
1.06
Market Cap:
$8.17B
Revenue:
$633.51M
Net Income/Loss:
$-8.10M
P/E Ratio:
-468.52
EPS:
-0.31
Net Cash Flow:
$131.26M
1W Performance:
-2.35%
1M Performance:
+20.80%
6M Performance:
+26.09%
1Y Performance:
+7.99%
1-Day Range:
$143.47
$148.96
1-Week Range:
$143.47
$153.02
52-Week Range:
$102.97
$182.52
Repligen Corp Stock (RGEN) Company Profile
Name
Repligen Corp
Sector
Industry
Phone
(781) 449-9560
Address
41 SEYON STREET, WALTHAM, MA
Compare RGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
145.24 | 8.37B | 633.51M | -8.10M | 131.26M | -0.31 |
|
ISRG
Intuitive Surgical Inc
|
429.59 | 159.08B | 9.15B | 2.63B | 1.99B | 7.1661 |
|
BDX
Becton Dickinson Co
|
186.56 | 54.20B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
RMD
Resmed Inc
|
272.00 | 40.55B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
ALC
Alcon Inc
|
72.05 | 36.85B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
WST
West Pharmaceutical Services Inc
|
261.77 | 18.95B | 2.96B | 487.70M | 344.00M | 6.6758 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-25 | Initiated | HSBC Securities | Buy |
| Sep-22-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-22-25 | Resumed | Stephens | Overweight |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-29-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | Evercore ISI | In-line |
| Feb-10-25 | Initiated | TD Cowen | Buy |
| Dec-17-24 | Initiated | Canaccord Genuity | Hold |
| Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-26-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jun-18-24 | Initiated | Guggenheim | Neutral |
| Dec-04-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-20-23 | Initiated | Wells Fargo | Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Mar-28-23 | Initiated | The Benchmark Company | Buy |
| Dec-14-22 | Initiated | Deutsche Bank | Hold |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-22 | Initiated | UBS | Buy |
| Oct-14-21 | Initiated | Exane BNP Paribas | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| May-07-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-23-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Nov-01-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Oct-15-19 | Initiated | SVB Leerink | Outperform |
| Aug-28-19 | Reiterated | First Analysis Sec | Outperform |
| Aug-23-19 | Resumed | Stephens | Overweight |
| Jul-22-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-17-18 | Upgrade | CL King | Neutral → Buy |
| Nov-12-18 | Downgrade | CL King | Buy → Neutral |
| Sep-26-18 | Initiated | H.C. Wainwright | Neutral |
| Dec-08-17 | Initiated | Citigroup | Buy |
| Dec-05-17 | Initiated | JP Morgan | Overweight |
| Nov-13-17 | Initiated | CL King | Buy |
| Oct-02-17 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Jul-21-17 | Initiated | William Blair | Outperform |
| Feb-13-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Repligen Corp Stock (RGEN) Latest News
Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know - Barchart.com
Hollow Fiber Filtration Market Is Booming Worldwide 2025-2032 | - openPR.com
Is Repligen (RGEN) The Best Healthcare Stock to Buy Now? - Insider Monkey
Repligen Corporation’s volatility index tracking explainedWall Street Watch & Verified Trade Idea Suggestions - newser.com
Can technical indicators confirm Repligen Corporation’s reversal - newser.com
Repligen Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Repligen’s SWOT analysis: bioprocessing leader faces growth challenges - Investing.com
Evercore ISI Issues Positive Forecast for Repligen (NASDAQ:RGEN) Stock Price - Defense World
RGEN: Evercore ISI Group Maintains "Outperform" Rating, Raises P - GuruFocus
Evercore Maintains Repligen(RGEN.US) With Buy Rating, Raises Target Price to $175 - 富途牛牛
Repligen (RGEN): Assessing Valuation Following HSBC’s Positive Coverage and Renewed Biotech Optimism - simplywall.st
Short interest data insights for Repligen CorporationMarket Volume Report & Safe Entry Point Alerts - newser.com
Is Repligen Corporation stock affected by interest rate hikesGlobal Markets & AI Forecast for Swing Trade Picks - newser.com
What indicators show strength in Repligen Corporation2025 Historical Comparison & Weekly Setup with High ROI Potential - newser.com
Can New Analyst Attention on RGEN Reveal the True Strength of Repligen's Bioprocessing Edge? - simplywall.st
Is Repligen’s Recent 18% Price Surge Justified After Broad Biotech Rally? - Yahoo Finance
Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) 28% Share Price Surge - simplywall.st
Why Repligen Corporation stock attracts global investorsMarket Sentiment Report & Real-Time Volume Analysis - newser.com
Key metrics from Repligen Corporation’s quarterly dataWeekly Trade Report & Community Shared Stock Ideas - newser.com
Why Repligen Corporation stock is a must watch in 2025July 2025 Movers & Accurate Intraday Trading Signals - newser.com
Published on: 2025-10-03 00:54:45 - newser.com
Applying big data sentiment scoring on Repligen Corporation2025 Risk Factors & Reliable Breakout Forecasts - newser.com
GAMMA Investing LLC Sells 132 Shares of Repligen Corporation $RGEN - Defense World
Repligen (RGEN) Poised for Rebound Amid Market Shifts - GuruFocus
What 8 Analyst Ratings Have To Say About Repligen - Benzinga
Best Manufacturing Stocks To Follow TodayOctober 1st - MarketBeat
Repligen (RGEN) Receives "Buy" Rating from HSBC with Target Pric - GuruFocus
Why Is Repligen (RGEN) Stock Soaring Today - Yahoo Finance
Repligen (RGEN) Gains Momentum with HSBC's Buy Rating and Strong Growth Outlook - GuruFocus
HSBC initiates coverage on Repligen stock with Buy rating, $150 target - Investing.com
Repligen, BrightSpring Health Services, Danaher, Thermo Fisher, and Amgen Shares Skyrocket, What You Need To Know - Yahoo Finance
Fifth Third Bancorp Reduces Stock Position in Repligen Corporation $RGEN - Defense World
What analysts say about Repligen Corporation RGN stockGlobal Trade Effects & Free Popular Stock Picks Selection - earlytimes.in
Is Repligen Corporation (RGN) stock bottoming after sell offJuly 2025 Drop Watch & Comprehensive Market Scan Insights - newser.com
How Repligen Corporation stock performs in interest rate cycles2025 Top Decliners & Safe Capital Growth Trade Ideas - newser.com
What data driven models say about Repligen Corporation’s future2025 Performance Recap & Comprehensive Market Scan Insights - newser.com
Repligen Corporation $RGEN Shares Bought by Congress Asset Management Co. - MarketBeat
Why Repligen Corporation (RGN) stock remains stableEarnings Overview Summary & Weekly Top Stock Performers List - newser.com
Why Repligen Corporation stock remains a top recommendationEarnings Performance Report & AI Powered Market Entry Strategies - newser.com
Repligen Corp Stock (RGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Repligen Corp Stock (RGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hunt Anthony | Director |
Sep 10 '25 |
Sale |
120.52 |
29,111 |
3,508,389 |
100,743 |
1.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):